SOHO Annual Meeting | Conferences

Concomitant Steroids and Mogamulizumab Lead to Greater Response Rate in MF/SS, Suggests Benefit for Real-World Use

September 11, 2020

Responses were improved for patients receiving treatment with mogamulizumab with the use of concomitant topical steroids compared with the overall study population in the phase 3 MAVORIC study of patients with mycosis fungoides or Sézary syndrome, according to the results of a post hoc analysis of the study.

HIV-Positivity in Classic Hodgkin Lymphoma Shows Comparable Outcomes to Patients Without HIV

September 11, 2020

Patients with classic Hodgkin lymphoma and human immunodeficiency virus were found to have similar clinical outcomes compared with patients with cHL and no HIV, according to an analysis presented during the eighth annual virtual meeting of the Society of Hematologic Oncology.

Daratumumab Leads to Deep Responses Among Newly Diagnosed Black Patients With Multiple Myeloma

September 10, 2020

Adding the anti-CD38 antibody, daratumumab, to the standard of care regimen of lenalidomide, bortezomib, and dexamethasone, improved depth of response, stringent complete response , and minimal residual disease negativity, in a subgroup of Black patients who had newly diagnosed multiple myeloma, according to findings presented at the eighth annual Society of Hematologic Oncology meeting.

Prognostic Factors Suggest Benefit for Some With Myeloablative Busulfan/Fludarabine Conditioning in Myelofibrosis

September 10, 2020

Prognostic factors in patients with myelofibrosis treated with a myeloablative busulfan/fludarabine conditioning regimen prior to allogeneic stem cell transplantation in a single-institution analysis showed that a time from diagnosis to transplant of more than 12 months was associated with poorer overall survival and displayed a trend toward higher non-relapse mortality.

Modified Pediatric Regimen Improves Outcomes in Young Adult Patients With Acute Lymphoblastic Leukemia

September 09, 2020

Using a modified pediatric regimen to treat adolescents and young adults with acute lymphoblastic leukemia led to superior outcomes compared with historical adult ALL regimen results, according to a retrospective analysis that evaluated 95 AYAs aged 14 to 39 years. Findings were presented at the eighth annual Society of Hematologic Oncology virtual meeting.

Considerations for Choosing Between Newer Agents in R/R B-Cell ALL

September 09, 2020

In the past 5 years, 3 new treatment options have emerged to treat patients with relapsed or refractory acute lymphoblastic leukemia, providing hope for patients with this disease, but also raising clinical questions of how to choose among these agents and what is the best option for the patient at which time.

Real-World Data Show Tisagenlecleucel is an Effective Treatment for DLBCL

September 15, 2019

In a prospective postmarketing assessment, the use of tisagenlecleucel for treatment of adult patients with diffuse large B-cell lymphoma, lead to responses that were similar to studies of children and adolescents with B-cell acute lymphoblastic leukemia.

More Research and Development on JAK Inhibition May Improve Myelofibrosis Management

September 15, 2019

In an interview with Targeted Oncology during the 2019 SOHO Annual Meeting, Laura C. Michaelis, MD, discussed the currently approved JAK inhibitors and the future landscape for myelofibrosis, as well as treatment considerations for graft-versus-host disease.